Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso

Decosas, Josef; Koama, Jean-Baptiste T

doi:10.1016/s1473-3099(02)00455-3

Cited by 82 publications

(47 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2000, a W-135 outbreak occurred in Saudi Arabia during the annual Hajj pilgrimage (79,229,275,(335)(336)(337). The outbreak strain spread to multiple other countries and caused a large epidemic in Burkina Faso in 2002.…”

Section: Meningococcal Serogroupsmentioning

confidence: 99%

“…The project is working with a developing country vaccine manufacturer to develop a vaccine at a price of under US$0.50 (http://www .meningvax.org/files/essay-fmlaforce-0311.pdf, last accessed 12 December 2005). Given the recent emergence of epidemic W-135 disease in Africa and elsewhere (79,211) as well as outbreaks of serogroup X infection (88,127), future vaccine development for Africa may need to include serogroups other than just serogroup A.…”

Section: Prevention In the Developing Worldmentioning

confidence: 99%

See 1 more Smart Citation

Prospects for Vaccine Prevention of Meningococcal Infection

2006

View full text Add to dashboard Cite

SUMMARY Neisseria meningitidis is the leading cause of bacterial meningitis in the United States and worldwide. A serogroup A/C/W-135/Y polysaccharide meningococcal vaccine has been licensed in the United States since 1981 but has not been used universally outside of the military. On 14 January 2005, a polysaccharide conjugate vaccine that covers meningococcal serogroups A, C, W-135, and Y was licensed in the United States for 11- to 55-year-olds and is now recommended for the routine immunization of adolescents and other high-risk groups. This review covers the changing epidemiology of meningococcal disease in the United States, issues related to vaccine prevention, and recommendations on the use of the new vaccine.

show abstract

Section: Meningococcal Serogroupsmentioning

confidence: 99%

Section: Prevention In the Developing Worldmentioning

confidence: 99%

Prospects for Vaccine Prevention of Meningococcal Infection

2006

View full text Add to dashboard Cite

show abstract

“…Most African epidemics have been caused by meningococci belonging to serogroup A (Greenwood 1999) but outbreaks caused by meningococci belonging to serogroup C, W or X meningococci have been reported (Broome et al 1983;Decosas & Koama 2002;Boisier et al 2007;Halperin et al 2012).…”

Section: Introductionmentioning

confidence: 99%

Meningococcal carriage in the African meningitis belt

Trotter

Greenwood

2007

The Lancet Infectious Diseases

141

125

View full text Add to dashboard Cite

“…The second, in Burkina Faso in 2002, also involved ST-11 strain type W:2a: P1.5,2, although using variable-number tandem repeat analysis, this strain was found to differ from that causing disease in Saudi Arabia (29). Burkina Faso was the first country in the world to have a group W135 strain as the predominant diseasecausing strain (9). In sharp contrast, only one case of disease caused by the W:2a:P1.5,2 strain type was recorded in New Zealand prior to 2003 (our unpublished data).…”

mentioning

confidence: 99%

Evidence for Capsule Switching between Carried and Disease-CausingNeisseria meningitidisStrains

Beddek

Kroll

et al. 2009

Infect Immun

View full text Add to dashboard Cite

Changing antigenic structure such as with capsule polysaccharide is a common strategy for bacterial pathogens to evade a host immune system. The recent emergence of an invasive W:2a:P1.7-2,4 sequence type 11 (ST-11) strain of Neisseria meningitidis in New Zealand, an uncommon serogroup/serotype in New Zealand disease cases, was investigated for its genetic origins. Molecular typing of 107 meningococcal isolates with similar serotyping characteristics was undertaken to determine genetic relationships. Results indicated that the W:2a:P1.7-2,4 strain had emerged via capsule switching from a group C strain (C:2a:P1.7-2,4). Neither the upstream nor downstream sites of recombination could be elucidated, but sequence analysis demonstrated that at least 45 kb of DNA was involved in the recombination, including the entire capsule gene cluster. The oatWY gene carried by the W:2a:P1.7-2,4 strain contained the insertion sequence element IS1301, one of five variants of oatWY found in group W135 strains belonging to the carriage-associated ST-22 clonal complex. This suggested that the origin of the capsule genes carried by the invasive W:2a:P1.7-2,4 strain is carriage associated. These results provide novel evidence for the long-standing dogma that disease-associated strains acquire antigenic structure from carriage-associated strains. Moreover, the capsule switch described here has arisen from the exchange of the entire capsule locus.

show abstract

Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso

Cited by 82 publications

References 9 publications

Prospects for Vaccine Prevention of Meningococcal Infection

Prospects for Vaccine Prevention of Meningococcal Infection

Meningococcal carriage in the African meningitis belt

Evidence for Capsule Switching between Carried and Disease-CausingNeisseria meningitidisStrains

Contact Info

Product

Resources

About